BTIG initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $50 price target The firm says Ascentage has a “validated” apoptosis-targeted platform and two late-stage assets, Olverembatinib and Lisaftoclax, to drive sustained commercial growth and valuation upside. BTIG views Ascentage as one of the “most compelling” China-based biopharma stocks. The company is positioned to for “sustainable global relevance” as it transitions from clinical-stage to commercial-scale, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AAPG:
- Pinterest downgraded, Tractor Supply upgraded: Wall Street’s top analyst calls
- Ascentage Pharma initiated with an Overweight at Piper Sandler
- Promising Potential of Ascentage Pharma’s Key Assets: Olverembatinib and Lisaftoclax Drive Buy Rating Amidst Risks
- Ascentage Pharma to Engage Investors at November Conferences
- Ascentage Pharma Engages Investors at October 2025 Conferences